Updates
Company and scientific updates appear here after editorial and corporate review.
Partnership
SiVEC and RheumaGen entered a licensing and joint development partnership to advance HLA-targeted, in vivo gene-editing therapies for autoimmune diseases.
October 7, 2025
Awards
SiVEC was recognized in the 2024 BioChallenge pitch competition and secured a share of the $100,000 prize pool.
November 6, 2024
Awards
SiVEC was selected as a Phase 1 winner in the NIH TARGETED Genome Editor Delivery Challenge.
December 13, 2023
Awards
Dr. Lyndsey Linke was awarded first place in the Innovator’s Pitch Challenge at Digital RESI March.
April 27, 2023
Publication
A peer-reviewed paper describes the safety and efficacy of SiVEC’s live bacterial delivery vehicle.
February 5, 2023
Awards
SiVEC was recognized as the top emerging start-up company after competing in the 2022 BIO International Start-Up Stadium.
September 14, 2022
